An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

In an open-label, phase II study, we evaluated entospletinib monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma. Entospletinib had limited activity in these patients. Seventy-four percent of the patients experienced a grade ≥ 3 adverse event. Treatment was interrupted...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Lymphoma Myeloma Leuk
Main Authors: Burke, John M., Shustov, Andrei, Essell, James, Patel-Donnelly, Dipti, Yang, Jay, Chen, Robert, Ye, Wei, Shi, Wen, Assouline, Sarit, Sharman, Jeff
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6857170/
https://ncbi.nlm.nih.gov/pubmed/29934062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.05.022
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍